

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17349 A1(51) International Patent Classification⁷: A01N 43/56,
A61K 31/415, C07D 231/04(74) Agents: DUSTMAN, Wayne, J. et al.; SmithKline
Beecham Corporation, Corporate Intellectual Property,
UW2220, 709 Swedeland Road, P.O. Box 1539, King of
Prussia, PA 19406-0939 (US).

(21) International Application Number: PCT/US00/24665

(22) International Filing Date:
8 September 2000 (08.09.2000)(81) Designated States (*national*): AE, AL, AU, BA, BB, BG,
BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK,
MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT,
TZ, UA, US, UZ, VN, YU, ZA.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/153,358 10 September 1999 (10.09.1999) US
60/203,668 12 May 2000 (12.05.2000) US(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*):
SMITHKLINE BECKMAN CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LUENGO, Juan, I.
[ES/US]; 701 Pondview Drive, Audubon, PA 19403 (US).
DUFFY, Kevin, J. [GB/US]; 712 Mill Grove Drive, Nor-
ristown, PA 19403 (US).For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THROMBOPOIETIN MIMETICS

(57) Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

WO 01/17349 A1

THROMBOPOIETIN MIMETICS

FIELD OF THE INVENTION

5 This invention relates to thrombopoietin (TPO) mimetics and their use as promoters of thrombopoiesis and megakaryocytopoiesis.

BACKGROUND OF THE INVENTION

10 Megakaryocytes are bone marrow-derived cells, which are responsible for producing circulating blood platelets. Although comprising <0.25% of the bone marrow cells in most species, they have >10 times the volume of typical marrow cells. See Kuter et al. Proc. Natl. Acad. Sci. USA 91: 11104-11108 (1994). Megakaryocytes undergo a process known as endomitosis whereby they replicate their nuclei but fail to undergo cell division and thereby give rise to polyploid cells. In response to a decreased platelet count, the endomitotic rate increases, higher ploidy megakaryocytes are formed, and the number of megakaryocytes may increase up to 3-fold. See Harker J. Clin. Invest. 47: 458-465 (1968). In contrast, in response to an elevated platelet count, the endomitotic rate decreases, lower ploidy megakaryocytes are formed, and the number of megakaryocytes may decrease by 50%.

20 The exact physiological feedback mechanism by which the mass of circulating platelets regulates the endomitotic rate and number of bone marrow megakaryocytes is not known. The circulating thrombopoietic factor involved in mediating this feedback loop is now thought to be thrombopoietin (TPO). More specifically, TPO has been shown to be the main humoral regulator in situations involving thrombocytopenia. See, e.g., Metcalf Nature 369:519-520 (1994). TPO has been shown in several studies to increase platelet counts, increase platelet size, 25 and increase isotope incorporation into platelets of recipient animals. Specifically, TPO is thought to affect megakaryocytopoiesis in several ways: (1) it produces increases in megakaryocyte size and number; (2) it produces an increase in DNA content, in the form of polyploidy, in megakaryocytes; (3) it increases megakaryocyte endomitosis; (4) it produces increased maturation of megakaryocytes; and (5) it produces an increase in the percentage of precursor cells, in the form of small acetylcholinesterase-positive cells, in the bone marrow. 30

Because platelets (thrombocytes) are necessary for blood clotting and when their numbers are very low a patient is at risk of death from catastrophic hemorrhage, TPO has potential useful application in both the diagnosis and the treatment of various hematological disorders, for example, diseases primarily due to platelet defects. Ongoing clinical trials with TPO have indicated that TPO can be administered safely to patients. 35 In addition, recent studies have provided a basis for the projection of efficacy of TPO therapy in the treatment of thrombocytopenia, and particularly thrombocytopenia resulting from

chemotherapy, radiation therapy, or bone marrow transplantation as treatment for cancer or lymphoma. See e.g., McDonald (1992) Am. J. Ped. Hematology/Oncology 14: 8-21 (1992).

The gene encoding TPO has been cloned and characterized. See Kuter et al.,
5 Proc. Natl. Acad. Sci. USA 91: 11104-11108 (1994); Barley et al., Cell 77:
1117-1124 (1994); Kaushansky et al., Nature 369:568-571 (1994); Wendling et al.,
Nature 369: 571-574 (1994); and Sauvage et al., Nature 369: 533-538 (1994).
Thrombopoietin is a glycoprotein with at least two forms, with apparent molecular masses of
25 kDa and 31 kDa, with a common N-terminal amino acid sequence. See, Bartley, et al.,
10 Cell 77: 1117-1124 (1994). Thrombopoietin appears to have two distinct regions separated
by a potential Arg-Arg cleavage site. The amino-terminal region is highly conserved in man
and mouse, and has some homology with erythropoietin and interferon-a and interferon-b.
The carboxy-terminal region shows wide species divergence.

The DNA sequences and encoded peptide sequences for human TPO receptor (TPO-
15 R; also known as c-mpl) have been described. See, Vigon et al. Proc. Natl. Acad. Sci. USA
89: 5640-5644. (1992). TPO-R is a member of the haematopoietin growth factor receptor
family, a family characterized by a common structural design of the extracellular domain,
including for conserved C residues in the N-terminal portion and a WSXWS motif close to
the transmembrane region. See Bazan Proc. Natl. Acad. Sci. USA 87: 6934-6938 (1990).
20 Evidence that this receptor plays a functional role in hematopoiesis includes observations
that its expression is restricted to spleen, bone marrow, or fetal liver in mice (see Souyri et
al. Cell 63: 1137-1147 (1990)) and to megakaryocytes, platelets, and CD34⁺ cells in
humans (see Methia et al. Blood 82: 1395-1401 (1993)). Further evidence for TPO-R as a
key regulator of megakaryopoiesis is the fact that exposure of CD34⁺ cells to synthetic
25 oligonucleotides antisense to TPO-R RNA significantly inhibits the appearance of
megakaryocyte colonies without affecting erythroid or myeloid colony formation. Some
workers postulate that the receptor functions as a homodimer, similar to the situation with
the receptors for G-CSF and erythropoietin.


The slow recovery of platelet levels in patients suffering from thrombocytopenia is a
30 serious problem, and has lent urgency to the search for a blood growth factor agonist able to
accelerate platelet regeneration.

It would be desirable to provide compounds which allow for the treatment of
thrombocytopenia by acting as a TPO mimetic.

As disclosed herein it has unexpectedly been discovered that certain hydroxy-1-azo-
35 benzene derivatives are effective as agonists of the TPO receptor, they are potent TPO
mimetics.

SUMMARY OF THE INVENTION

This invention relates to compounds of Formula (I):



wherein:

R, R¹, R², R³ and R⁹ are each independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_pOR⁴, -C(O)OR⁴, nitro, cyano, halogen, aryl, -S(O)_nR⁴, cycloalkyl, protected -OH, -CONR⁵R⁶, phosphonic acid, sulfonic acid, phosphinic acid and -SO₂NR⁵R⁶,

where

p is 0-6;

n is 0-2;

R⁴ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and

R⁵ and R⁶ are each independently selected from hydrogen, alkyl, C₃₋₆cycloalkyl, and aryl,

or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen;

m is 0-6; and

R¹⁰ is a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one

heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aryloxy, alkoxy, acyloxy, amino, nitro, cyano, halogen, hydroxy, protected -OH, and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, aryloxy, amino, nitro, cyano, halogen, hydroxy, and protected -OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;


provided that:

at least one of R, R¹, R² and R³ is: sulfonic acid, -C(O)OR⁴, tetrazole, -CONR⁵R⁶, phosphonic acid or phosphinic acid; where R⁴, R⁵ and R⁶ are as described above;

and provided that:

when R¹ is carboxylic acid; R, R² and R³ are hydrogen; and R⁹ is methyl; R¹⁰ is not unsubstituted phenyl.

This invention relates to a method of treating thrombocytopenia, which comprises administering to a subject in need thereof an effective amount of a TPO mimetic compound of Formula (II):



wherein:

R, R¹, R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl,

C_{1-6} alkoxy, $-(CH_2)_pOR^4$, $-C(O)OR^4$, nitro, cyano, halogen, aryl, $-S(O)_nR^4$, cycloalkyl, protected $-OH$, $-CONR^5R^6$, $-NR^5R^6$, phosphonic acid, sulfonic acid, phosphinic acid and $-SO_2NR^5R^6$,

where

p is 0-6;

n is 0-2;

R^4 is hydrogen, alkyl, cycloalkyl, C_1-C_{12} aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12} aryl and

R^5 and R^6 are each independently selected from hydrogen, alkyl, C_3-

6cycloalkyl, and aryl,

or R^5 and R^6 taken together with the nitrogen to which they are attached

represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen;

m is 0-6; and

AR is cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, $-C(O)OR^4$, $-C(O)NR^7R^8$, $-S(O)_2NR^7R^8$, $-S(O)_nR^4$, protected $-OH$ and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, $-C(O)OR^4$, $-C(O)NR^7R^8$, $-S(O)_2NR^7R^8$, $-S(O)_nR^4$, aryloxy, nitro, cyano, halogen, and protected $-OH$,

where

R^4 is hydrogen, alkyl, cycloalkyl, C_1-C_{12} aryl, substituted alkyl, substituted cycloalkyl and substituted C_1-C_{12} aryl; and

R^7 and R^8 are independently hydrogen, cycloalkyl, C_1-C_{12} aryl, substituted cycloalkyl, substituted C_1-C_{12} aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^4$, $-S(O)_nR^4$, $-C(O)NR^4R^4$, $-S(O)_2NR^4R^4$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C_1-C_{12} aryl, substituted C_1-C_{12} aryl and protected $-OH$,

or R⁷ and R⁸ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen,

where R⁴ is as described above and n is 0-2; and

5 pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

The present invention also relates to the discovery that the compounds of Formula (II) are active as agonists of the TPO receptor.

10 In a further aspect of the invention there is provided novel processes and novel intermediates useful in preparing the presently invented TPO mimetic compounds.

Included in the present invention are pharmaceutical compositions comprising a pharmaceutical carrier and compounds useful in the methods of the invention.

15

Also included in the present invention are methods of co-administering the presently invented TPO mimetic compounds with further active ingredients.

DETAILED DESCRIPTION OF THE INVENTION

20

The presently invented compounds that act as TPO mimetics are defined by Formula (I) above.

Preferred among the presently invented Formula I compounds are those in which
25 R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, carboxylic acid, C₁-C₁₂aryl, sulfonic acid, tetrazole, -CONR⁵R⁶ where R⁵ and R⁶ are as described in Formula I above, phosphonic acid, phosphinic acid, C₁-6alkoxy, nitro, C₁-6alkyl and halogen; m is 0; R⁹ is C₁-6alkyl, C₁-6alkoxy, halogen, or C₁-C₁₂aryl; and R¹⁰ is a cyclic or polycyclic aromatic ring containing from 3 to 14 carbon atoms,
30 optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, C₁-C₁₂aryl, substituted cycloalkyl, substituted C₁-C₁₂aryl, aryloxy, alkoxy, trifluoromethyl,
35 cycloalkyl, nitro, cyano, hydroxy, halogen and protected -OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Particularly preferred among the presently invented Formula I compounds are those in which R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, C₁₋₆alkoxy, tetrazole, -CONR⁵R⁶ where R⁵ and R⁶ are as described in Formula I above, phosphonic acid, phosphinic acid, C₁₋₆alkyl and halogen; m is 0; R⁹ is C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or C₁-C₁₂aryl; and R¹⁰ is phenyl substituted with one or more substituents selected from the group consisting of: alkyl, substituted alkyl, alkoxy, trifluoromethyl, halogen, hydroxy and protected -OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

The most preferred among the presently invented Formula I compounds are those in which R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, C₁₋₆alkoxy, C₁₋₆alkyl and halogen; m is 0; R⁹ is C₁₋₆alkyl or C₁₋₆alkoxy and R¹⁰ is phenyl substituted with from one to three substituents selected from the group consisting of: alkyl, hydroxy, alkoxy, trifluoromethyl and halogen; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Preferred among the presently invented compounds of Formula I are

3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
 4-([1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 4-([1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 4-([1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-4-hydroxybenzoic acid;
 3-hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid;

2-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 5-chloro-3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzenesulfonic acid;
 5 3-*tert*-butyl-4-([1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 methyl 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoate; and
 10 4-([1-(4-*tert*-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
 and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

15 This invention relates to a method of treating thrombocytopenia, which comprises administering to a subject in need thereof an effective amount of a TPO mimetic compound defined by Formula (II) above.

Preferred among the compounds of Formula II are those in which R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, 20 carboxylic acid, C₁-C₁₂aryl, sulfonic acid, tetrazole, -CONR⁵R⁶ where R⁵ and R⁶ are as described in Formula II above, phosphonic acid, phosphinic acid, C₁-₆alkoxy, nitro, C₁-₆alkyl and halogen; m is 0; and AR is a cyclic or polycyclic aromatic ring containing from 3 to 14 carbon atoms, optionally containing one or more heteroatoms, provided that when 25 the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, C₁-C₁₂ aryl, substituted cycloalkyl, substituted C₁-C₁₂aryl, aryloxy, hydroxy, alkoxy, cycloalkyl, amino, nitro, cyano, halogen and protected -OH; and 30 pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Particularly preferred among the compounds of Formula II are those in which R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, C₁-₆alkoxy, tetrazole, -CONR⁵R⁶ where R⁵ and R⁶ are as described in Formula 35 II above, phosphonic acid, phosphinic acid, C₁-₆alkyl and halogen; m is 0; and AR is a cyclic or polycyclic aromatic ring containing from 3 to 14 carbon atoms, optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3

the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, C₁-C₁₂ aryl, substituted C₁-C₁₂aryl, aryloxy, hydroxy, alkoxy, amino, halogen and protected -OH; and
 5 pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

The most preferred among the compounds of Formula II are those in which R¹ is carboxylic acid or sulfonic acid; R, R² and R³ are each independently selected from hydrogen, C₁-6alkoxy, C₁-6alkyl and halogen; m is 0; and AR is selected from
 10 naphthalene, phenyl and pyrazole, and optionally substituted with from one to three substituents selected from the group consisting of: alkyl, C₁-C₁₂ aryl, substituted C₁-C₁₂aryl, hydroxy, alkoxy and halogen; and
 pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

15 Preferred among the compounds of Formula II are

- 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
- 3-hydroxy-4-([5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl]azo)benzoic acid;
- 20 4-([1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
- 4-([1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
- 4-([1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
- 25 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
- 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-4-hydroxybenzoic acid;
- 30 3-hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
- 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
- 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid;
- 35 2-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;

5-chloro-3-{{1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl}azo}-2-hydroxybenzenesulfonic acid;
3-*tert*-butyl-4-{{1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl}azo}-3-hydroxybenzoic acid;
5 4-{{1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl}azo}-3-hydroxybenzoic acid;
methyl 3-hydroxy-4-{{5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl}azo}benzoate; and
4-{{1-(4-*tert*-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl}azo}-3-
10 hydroxybenzoic acid;
and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

Compounds of Formula (I) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.

15

Compounds of Formula (II) are included in the pharmaceutical compositions of the invention and used in the methods of the invention.

By the term "protected hydroxy" or "protected -OH" as used herein, is meant the alcoholic or carboxylic-OH groups which can be protected by conventional blocking groups in the art such as described in "Protective Groups In Organic Synthesis" by Theodora W. Greene, Wiley-Interscience, 1981, New York. Compounds containing protected hydroxy groups may also be useful as intermediates in the preparation of the pharmaceutically active compounds of the invention.

25

By the term "aryl" as used herein, unless otherwise defined, is meant a cyclic or polycyclic aromatic ring containing from 1 to 14 carbon atoms and optionally containing from one to five heteroatoms, provided that when the number of carbon atoms is 1 the aromatic ring contains at least four heteroatoms, when the number of carbon atoms is 2 the aromatic ring contains at least three heteroatoms, when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom.

By the term "C₁-C₁₂aryl" as used herein, unless otherwise defined, is meant phenyl, naphthalene, 3,4-methylenedioxyphenyl, pyridine, biphenyl, quinoline, pyrimidine, quinazoline, thiophene, furan, pyrrole, pyrazole, imidazole and tetrazole.

35

By the term "substituted" as used herein, unless otherwise defined, is meant that the subject chemical moiety has one or more substituents selected from the group consisting of: hydroxyalkyl, alkoxy, acyloxy, alkyl, amino, N-acylamino, hydroxy, $-(CH_2)_gC(O)OR^{11}$, $-S(O)_nR^{12}$, nitro, cyano, halogen, trifluoromethyl and protected -OH, where g is 0-6, R^{11} is hydrogen or alkyl, n is 0-2, and R^{12} is hydrogen or alkyl.

By the term "alkoxy" as used herein is meant -Oalkyl where alkyl is as described herein including $-OCH_3$ and $-OC(CH_3)_2CH_3$.

The term "cycloalkyl" as used herein unless otherwise defined, is meant a nonaromatic, unsaturated or saturated, cyclic or polycyclic C_3 - C_{12} .

Examples of cycloalkyl and substituted cycloalkyl substituents as used herein include: cyclohexyl, 4-hydroxy-cyclohexyl, 2-ethylcyclohexyl, propyl 4-methoxycyclohexyl, 4-methoxycyclohexyl, 4-carboxycyclohexyl and cyclopentyl.

By the term "acyloxy" as used herein is meant $-OC(O)alkyl$ where alkyl is as described herein. Examples of acyloxy substituents as used herein include: $-OC(O)CH_3$, $-OC(O)CH(CH_3)_2$ and $-OC(O)(CH_2)_3CH_3$.

By the term "N-acylamino" as used herein is meant $-N(H)C(O)alkyl$, where alkyl is as described herein. Examples of N-acylamino substituents as used herein include: $-N(H)C(O)CH_3$, $-N(H)C(O)CH(CH_3)_2$ and $-N(H)C(O)(CH_2)_3CH_3$.

By the term "aryloxy" as used herein is meant $-OC_6-C_{12}aryl$ where $C_6-C_{12}aryl$ is phenyl, naphthyl, 3,4-methylenedioxyphenyl, pyridyl or biphenyl optionally substituted with one or more substituents selected from the group consisting of: alkyl, hydroxyalkyl, alkoxy, trifluoromethyl, acyloxy, amino, N-acylamino, hydroxy, $-(CH_2)_gC(O)OR^{11}$, $-S(O)_nR^{12}$, nitro, cyano, halogen and protected -OH, where g is 0-6, R^{11} is hydrogen or alkyl, n is 0-2 and R^{12} is hydrogen or alkyl. Examples of aryloxy substituents as used herein include: phenoxy, 4-fluorophenoxy and biphenyloxy.

By the term "heteroatom" as used herein is meant oxygen, nitrogen or sulfur.

By the term "halogen" as used herein is meant a substituent selected from bromide, iodide, chloride and fluoride.

By the term "alkyl" and derivatives thereof and in all carbon chains as used herein is meant a linear or branched, saturated or unsaturated hydrocarbon chain, and unless otherwise defined, the carbon chain will contain from 1 to 12 carbon atoms. Examples of alkyl substituents as used herein include: -CH₃, -CH₂-CH₃, -CH₂-CH₂-CH₃, -CH(CH₃)₂,
5 -C(CH₃)₃, -(CH₂)₃-CH₃, -CH₂-CH(CH₃)₂, -CH(CH₃)-CH₂-CH₃, -CH=CH₂, and -C≡C-CH₃.

By the term "treating" and derivatives thereof as used herein, is meant prophylactic or therapeutic therapy.

10


All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth.

Compounds of Formula (II) are included in the pharmaceutical compositions of the invention and used in the methods of the invention. Where a -COOH or -OH group is
15 present, pharmaceutically acceptable esters can be employed, for example methyl, ethyl, pivaloyloxymethyl, and the like for -COOH, and acetate maleate and the like for -OH, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

20


The novel compounds of Formula II are prepared as shown in Schemes I and II below, or by analogous methods, wherein R, R¹, R², R³, AR and m are as defined in Formula II and provided that the R' and m substituents and AR do not include any such
25 substituents that render inoperative the processes of Schemes I and II. All of the starting materials are commercially available or are readily made from commercially available starting materials by those of skill in the art.

Scheme I



- i) 4-amino-1-benzenesulfonic acid, NaNO_2 , NaHCO_3 , water; ii) NaHSO_3 , water; iii) NaNO_2 , HCl , water; iv) AR, NaHCO_3 , water.

- Scheme I outlines the formation of Formula II compounds. As used in scheme I the diazo compound (b) is prepared from the three hydroxybenzene compound (a) by treating (a) with 4-benzenediazonium sulfate in the presence of an appropriate base, preferably sodium hydrogen carbonate. Reduction of compound (b) with sodium hydrogen sulfite in water yielded the 2-aminohydroxybenzene compound (c). Compound (c) is diazotized by reaction with sodium nitrite and an appropriate acid, such as nitric acid, sulfuric acid or, preferably hydrochloric acid, in an appropriate aqueous solvent, such as water or, preferably an ethanol-water mixture to produce diazonium compound (d).
- Compound (e) is prepared by reacting compound (d) in a coupling reaction with an appropriate aryl species in the presence of a base, preferably sodium hydrogen carbonate, or an acid, preferably hydrochloric acid.

Scheme II

5 i) NaNO_2 , HCl , water then SnCl_2 , water; ii) AcOH , heat

Scheme II outlines the formation of pyrazoles for use in scheme I. An amine such as 4-methylaniline, compound (f), is diazotized by the action of sodium nitrite and an appropriate acid such as hydrochloric acid, nitric acid or sulfuric acid in an appropriate aqueous solvent system such as water or ethanol-water mixtures then reduced *in situ* by tin chloride to afford hydrazine, compound (g). The hydrazine is then condensed with a beta-keto ester such as ethyl acetoacetate, compound (h), in an appropriate solvent such as acetic acid or ethanol at an appropriate temperature typically 0-100° to give the corresponding pyrazole, compound (I) as described herein.

15

The treatment of thrombocytopenia, as described herein, is accomplished by enhancing the production of platelets.

By the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a TPO mimetic compound, as described herein, and a further active ingredient or ingredients, known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production. Preferably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.

Because the pharmaceutically active compounds of the present invention are active as TPO mimetics they exhibit therapeutic utility in treating thrombocytopenia and other conditions with depressed platelet production.

In determining potency as TPO mimetics, the following assays were employed:

Luciferase Assay

Compounds of the present invention were tested for potency as mimetics of the TPO receptor in a Luciferase assay such as described in Lamb, et al., Nucleic Acids Research 23: 3283-3289 (1995) and Seidel, et al., Proc. Natl. Acad. Sci. USA 92: 3041-3045 (1995) by substituting a TPO-responsive BaF3 cell line (Vigon et al. Proc. Natl. Acad. Sci. USA 1992, 89, 5640-5644) for the HepG2 cells utilized therein. The murine BaF3 cells express TPO receptors and closely match the pattern of STAT (signal transducers and activators of transcription) activation observed in primary murine and human bone marrow cells.

Some of the most preferred compounds of this invention were also active in an in vitro proliferation assay using the murine 32D-mpl cell line (Bartley, T. D. et al., Cell, 1994, 77, 1117-1124). 32D-mpl cells express Tpo-R and their survival is dependent on the presence of TPO. Likewise, some of the most preferred compounds of this invention were also positive in stimulating the maturation of megakaryocytes from human bone marrow cells. In this assay, purified human CD34+ progenitor cells were incubated in liquid culture with test compounds for 10 days and the number of cells expressing the transmembrane glycoprotein CD41 (gpIIb), a megakaryocytic marker, was then measured by flow cytometry (see Cwirla, S. E. et al Science, 1997, 276, 1696-1699).

The pharmaceutically active compounds within the scope of this invention are useful as TPO mimetics in mammals, including humans, in need thereof.

Some of the preferred compounds within the scope of the invention showed activation from about 4% to 100% control at a concentration of 0.1-10 uM in the luciferase assay. The preferred compounds of the invention also promoted the proliferation of 32D-mpl cells at a concentration of 0.1 to 100 uM. The preferred compounds of the invention also showed activity in the CD41 megakaryocytic assay at a concentration of 0.1 to 30 uM.

The present invention therefore provides a method of treating thrombocytopenia and other conditions with depressed platelet production, which comprises administering a compound of Formula (II), as defined above, and pharmaceutically acceptable salts, hydrates, solvates and esters thereof, in a quantity effective to enhance platelet production. The compounds of Formula (II) also provide for a method of treating the above indicated disease states because of their demonstrated ability to act as TPO mimetics. The drug may be administered to a patient in need thereof by any conventional route of administration,

including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intradermal, and parenteral.

The pharmaceutically active compounds of the present invention are incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutical carriers are employed. Solid carriers include, starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline, and water. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension.

The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating, and compressing, when necessary, for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products.

Doses of the presently invented pharmaceutically active compounds in a pharmaceutical dosage unit as described above will be an efficacious, nontoxic quantity preferably selected from the range of 0.001 - 100 mg/kg of active compound, preferably 0.001 - 50 mg/kg. When treating a human patient in need of a TPO mimetic, the selected dose is administered preferably from 1-6 times daily, orally or parenterally. Preferred forms of parenteral administration include topically, rectally, transdermally, by injection and continuously by infusion. Oral dosage units for human administration preferably contain from 0.05 to 3500 mg of active compound. Oral administration, which uses lower dosages is preferred. Parenteral administration, at high dosages, however, also can be used when safe and convenient for the patient.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular TPO mimetic in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition.

Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, diet, and time of administration.

The method of this invention of inducing TPO mimetic activity in mammals, including humans, comprises administering to a subject in need of such activity an effective TPO mimetic amount of a pharmaceutically active compound of the present invention.

5 The invention also provides for the use of a compound of Formula (II) in the manufacture of a medicament for use as a TPO mimetic.

10 The invention also provides for the use of a compound of Formula (II) in the manufacture of a medicament for use in therapy.

10 The invention also provides for the use of a compound of Formula (II) in the manufacture of a medicament for use in enhancing platelet production.

15 The invention also provides for the use of a compound of Formula (II) in the manufacture of a medicament for use in treating thrombocytopenia.

20 The invention also provides for a pharmaceutical composition for use as a TPO mimetic which comprises a compound of Formula (II) and a pharmaceutically acceptable carrier.

20 The invention also provides for a pharmaceutical composition for use in the treatment of thrombocytopenia which comprises a compound of Formula (II) and a pharmaceutically acceptable carrier.


25 The invention also provides for a pharmaceutical composition for use in enhancing platelet production which comprises a compound of Formula (II) and a pharmaceutically acceptable carrier.

30 No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

35 In addition, the pharmaceutically active compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to treat thrombocytopenia, including chemotherapy-induced thrombocytopenia and bone marrow transplantation and other conditions with depressed platelet production, or compounds known to have utility when used in combination with a TPO mimetic.

Contemplated Equivalents – It will be appreciated by the person of ordinary skill in the art that the compounds of Formula I and II may also exist in tautomeric forms, wherein the double bond that is drawn between the two nitrogen atoms exists between the lower nitrogen atom and the AR substituent. Tautomeric forms of the compounds of

5 Formula I and II are exemplified by the following Formula III



10 where the 'R' groups are as defined above. All such compounds are included in the scope of the invention and inherently included in the definition of the compounds of Formulas I and II.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following
15 Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

Experimental Details

20 Example 1

Preparation of 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid:

25 A solution of 4-amino-3-hydroxybenzoic acid (0.77g, 0.005 mol.) in 1N aqu. hydrochloric acid (15.0 mL) was cooled to 0°C and treated slowly with a solution of sodium nitrite (0.38 g; 0.0055 mol.) in water (5.0 mL). After addition the solution was stirred at 0°C for 10 min. then 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one (0.94 g; 0.005 mol.) was added in one portion. Ethanol (15.0 mL) was added followed by sat. aqu. sodium
30 hydrogen carbonate until the pH of the solution was 8 (ca. 10 mL needed). The red solution was then stirred at room temperature for 16h.

The mixture was filtered and the solid dissolved in 10% aqu. sodium hydroxide (50.0 mL). The red solution was extracted twice with ethyl acetate then acidified with 6N aqu. hydrochloric acid and filtered to give the title compound as a red solid (1.67 g; 95%). MS(ES) m/z 351 [M-H].

5

Example 2

Preparation of 3-hydroxy-4-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)azo]benzoic acid:

10

Following the procedure of Example 1, except substituting 3-methyl-1-phenyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as a red solid. MS(ES) m/z 351 [M-H].

15

Example 3

Preparation of 4-[[1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid:

20 a) 4-Benzyloxyphenylhydrazine

A solution of 4-benzyloxyaniline hydrochloride (11.3 g; 0.048 mole) in concentrated hydrochloric acid (40.0 mL) was cooled to 0° then treated dropwise with a solution of sodium nitrite (3.28 g; 0.048 mole) in water (20.0 mL). The mixture was stirred at 0° for a further 10 min. then poured into a cold (-10°) solution of tin dichloride hydrate (40.0g; 0.18 mole) in concentrated hydrochloric acid (40.0 mL). The mixture was allowed to warm to room temperature with stirring for 1h.

25

The mixture was basified with 10% aqu. sodium hydroxide, ethyl acetate (1L) was added and the mixture filtered to remove unwanted tin residues. The organic layer was then dried and evaporated to afford the title compound as a yellow solid (6.9 g; 67%). mp 105-107°.

30

b) 1-(4-Benzyloxyphenyl)-3-methyl-3-pyrazolin-5-one

A solution of the compound from Example 3a) (2.6 g; 0.012 mol.) and ethyl acetoacetate (1.60 mL; 0.012 mol.) in glacial acetic acid (50.0 mL) was stirred and heated at 100° for 24h.

35

The solvent was evaporated and the product purified by chromatography (silica gel, 50% ethyl acetate/hexanes), the title compound was prepared (2.0 g; 60%). MS(ES) m/z 281 [M+H].

5 c) 4-([1-(4-Benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid

Following the procedure of Example 1, except substituting 1-(4-benzyloxyphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, and
10 followed by chromatography (silica gel, 10% methanol/ethyl acetate), the title compound was prepared as a brown powder (19%). mp = 258-260°C (decomp). Anal. (C₂₄H₂₀N₄O₅·CH₃OH) calcd: C, 63.00; H, 5.08; N, 11.76 found: C, 63.17; H, 4.64; N, 11.47.

15 Example 4

Preparation of 4-([1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid:

20 Following the procedure of Example 1, except substituting 1-(4-chlorophenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as a red solid. MS(ES) m/z 371, 373 [M-H].

Example 5

25

Preparation of 4-([1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid:

30 Following the procedure of Example 1, except substituting 1-(3-chlorophenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as a red solid. MS(ES) m/z 371, 373 [M-H].

Example 6

35 Preparation of 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid:

a) 1-(3,4-Dimethylphenyl)-3-phenyl-3-pyrazolin-5-one

Following the procedure of Example 3b), except substituting 3,4-dimethylphenylhydrazine for 4-benzyloxyphenylhydrazine, the title compound was prepared (16.0 g; 61%). MS(ES) m/z 265 [M+H].

b) 4-([1-(3,4-Dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as an orange solid (1.5 g, 82%). ¹H NMR (400 MHz, d₆-DMSO) δ 13.5 br s, 1H), 11.0 (s, 1H), 7.70 (m, 2H), 7.61 (dd, J = 8.2 and 2.1 Hz, 1H), 7.53 (m, 2H), 8.20 (d, J = 8.2 Hz, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.22 (s, 3H).

Example 7Preparation of 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-4-hydroxybenzoic acid:

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one and 3-amino-4-hydroxybenzoic acid for 4-amino-3-hydroxybenzoic acid, the title compound was prepared as an orange solid (1.5 g, 82%). ¹H NMR (400 MHz, d₆-DMSO) δ 13.5 br s, 1H), 11.7 (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.69-7.59 (m, 3H), 7.17 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 2.30 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H).

Example 8Preparation of 3-hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid:

a) 1-(3-Methylphenyl)-3-phenyl-3-pyrazolin-5-one

Following the procedure of Example 3b), except substituting 3-dimethylphenylhydrazine for 4-benzyloxyphenylhydrazine, the title compound was prepared (2.8 g; 90%). MS(ES) m/z 189 [M+H].

b) 3-Hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid

Following the procedure of Example 1, except substituting 1-(3-methylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as an orange solid (0.87 g; 50%). MS(ES) m/z 353 [M+H].

5

Example 9

Preparation of 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;

10 a) 3-Phenyl-1-(4-trifluoromethylphenyl)-3-pyrazolin-5-one

Following the procedure of Example 3b), except substituting 4-trifluoromethylphenylhydrazine for 4-benzyloxyphenylhydrazine, the title compound was prepared (3.3 g; 92%). MS(ES) m/z 243 [M+H].

15 b) 3-Hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid

Following the procedure of Example 1, except substituting 3-phenyl-1-(4-trifluoromethylphenyl)-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as an orange solid (0.86 g g; 35%). MS(ES) m/z 407 [M+H].

20

Example 10

Preparation of 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid;

25

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one and 3-amino-2-hydroxybenzoic acid for 4-amino-3-hydroxybenzoic acid, the title compound was prepared as an orange solid (0.40 g, 32%). ¹H NMR (400 MHz, d₆-DMSO) δ 7.83 (m, 2H), 7.59 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.60 (t, J = 7.8 Hz, 1H), 2.29 (s, 3H), 2.24 (s, 3H), 2.21 (s, 3H).

30

Example 11

35

Preparation of 5-chloro-3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzenesulfonic acid;

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one and 3-amino-5-chloro-2-hydroxybenzenesulfonic acid for 4-amino-3-hydroxybenzoic acid, the title compound was prepared as a red solid (0.74 g, 34%). mp 240°C (decomp). MS(ES) m/z 437, 435 [M-H].

Example 12

10 Preparation of 4-[[3-*tert*-butyl-1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid:

a) 3-*tert*-Butyl-1-(3,4-dimethylphenyl)-3-pyrazolin-5-one

Following the procedure of Example 3b), except substituting 3,4-dimethylphenylhydrazine for 4-benzyloxyphenylhydrazine and ethyl *tert*-butylacetate for ethyl acetoacetate, the title compound was prepared (25.1 g; 99%). MS(ES) m/z 245 [M+H].

b) 4-[[3-*tert*-Butyl-1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid

Following the procedure of Example 1, except substituting 3-*tert*-butyl-1-(3,4-dimethylphenyl)-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared (0.71 g; 70%) as an orange solid, MS(ES) m/z 409 [M+H].

25

Example 13

30 Preparation of 4-[[1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid:

a) 1-(3,4-Dimethylphenyl)-3-phenyl-3-pyrazolin-5-one

Following the procedure of Example 3b), except substituting 3,4-dimethylphenylhydrazine for 4-benzyloxyphenylhydrazine and ethyl benzoylacetate for ethyl acetoacetate, the title compound was prepared (16.0 g; 61%). MS(ES) m/z 265 [M+H].

35

b) 4-{{1-(3,4-Dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl}azo}-3-hydroxybenzoic acid

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-phenyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared (1.0 g; 78%) as a red solid, MS(ES) m/z 429 [M+H].

Example 14

Preparation of methyl 4-{{5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl}azo}-3-hydroxybenzoate

Following the procedure of Example 1, except substituting 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one and methyl 4-amino-3-hydroxybenzoate for 4-amino-3-hydroxybenzoic acid, the title compound was prepared as a red solid (0.059 g, 10%). MS(ES) m/z 367 [M+H].

Example 15

Preparation of 4-{{1-(4-tert-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl}azo}-3-hydroxybenzoate

Following the procedure of Example 1, except substituting 1-(4-tert-butylphenyl)-3-methyl-3-pyrazolin-5-one for 3-methyl-1-(4-methylphenyl)-3-pyrazolin-5-one, the title compound was prepared as an orange solid (0.895 g, 45%). MS(ES) m/z 395 [M+H], Anal. (C₂₁H₂₂N₄O₄) calcd: C, 63.95; H, 5.62; N, 14.20 found: C, 63.65; H, 5.75; N, 13.83.

Example 16 - Capsule Composition

An oral dosage form for administering a presently invented agonist of the TPO receptor is produced by filling a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.

Table I

35

INGREDIENTS

AMOUNTS

3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid (Compound 1)	25 mg
Lactose	55 mg
Talc	16 mg
Magnesium Stearate	4 mg

Example 17 - Injectable Parenteral Composition

An injectable form for administering a presently invented agonist of the TPO receptor is produced by stirring 1.5% by weight of 4-([1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid, monosodium salt (Compound 2) in 10% by volume propylene glycol in water.

Example 18 - Tablet Composition

The sucrose, calcium sulfate dihydrate and a presently invented agonist of the TPO receptor, as shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Table II

<u>INGREDIENTS</u>	<u>AMOUNTS</u>
4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid (Compound 6)	20 mg
calcium sulfate dihydrate	30 mg
sucrose	4 mg
starch	2 mg
talc	1 mg
stearic acid	0.5 mg

Preferred among the compounds of the present invention are the following;

3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
4-([1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;


- 4-([1-(4-tert-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid; and
5 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid.

The compound 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid demonstrated an activity of, $EC_{50} = 1.8 \mu M$, 50%TPO in
10 the above luciferase assay.

While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is
15 reserved.

What is claimed is:

1. A method of treating of thrombocytopenia in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Formula (II)



wherein:

R, R¹, R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_pOR⁴, -C(O)OR⁴, nitro, cyano, halogen, aryl, -S(O)_nR⁴, cycloalkyl, protected -OH, -CONR⁵R⁶, -NR⁵R⁶, phosphonic acid, sulfonic acid, phosphinic acid and -SO₂NR⁵R⁶,

where

p is 0-6;

n is 0-2;

R⁴ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl and

R⁵ and R⁶ are each independently selected from hydrogen, alkyl, C₃₋₆cycloalkyl, aryl or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen;

m is 0-6; and

AR is cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one

heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, aryl, substituted cycloalkyl, substituted aryl, aryloxy, hydroxy, alkoxy, cycloalkyl, acyloxy, amino, N-acylamino, nitro, cyano, halogen, $-C(O)OR^4$, $-C(O)NR^7R^8$, $-S(O)_2NR^7R^8$, $-S(O)_nR^4$, protected $-OH$ and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, amino, N-acylamino, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, $-C(O)OR^4$, $-C(O)NR^7R^8$, $-S(O)_2NR^7R^8$, $-S(O)_nR^4$, aryloxy, nitro, cyano, halogen, and protected $-OH$, where

R^4 is hydrogen, alkyl, cycloalkyl, C_1 - C_{12} aryl, substituted alkyl, substituted cycloalkyl and substituted C_1 - C_{12} aryl; and R^7 and R^8 are independently hydrogen, cycloalkyl, C_1 - C_{12} aryl, substituted cycloalkyl, substituted C_1 - C_{12} aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, $-C(O)OR^4$, $-S(O)_nR^4$, $-C(O)NR^4R^4$, $-S(O)_2NR^4R^4$, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C_1 - C_{12} aryl, substituted C_1 - C_{12} aryl and protected $-OH$, or R^7 and R^8 taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen, where R^4 is as described above and n is 0-2; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

2. The method of Claim 1 wherein the compound is selected from
 - 3-hydroxy-4-[[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo]benzoic acid;
 - 3-hydroxy-4-[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)azo]benzoic acid;
 - 4-[[1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;
 - 4-[[1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;
 - 4-[[1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;
 - 4-[[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;
 - 3-[[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-4-hydroxybenzoic acid;

- 3-hydroxy-4-{{[5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo}benzoic acid;
 3-hydroxy-4-{{[5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo}benzoic acid;
 5 3-{{[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-2-hydroxybenzoic acid;
 2-{{[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 5-chloro-3-{{[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-2-hydroxybenzenesulfonic acid;
 10 3-*tert*-butyl-4-{{[1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 4-{{[1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 15 methyl 3-hydroxy-4-{{[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo}benzoate; and
 4-{{[1-(4-*tert*-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

20

3. A method of enhancing platelet production in a mammal, including a human, in need thereof which comprises administering to such mammal a therapeutically effective amount of a compound of Claim 1.

25

4. The method of Claim 3 wherein the compound is selected from

- 3-hydroxy-4-{{[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo}benzoic acid;
 3-hydroxy-4-{{[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl]azo}benzoic acid;
 30 4-{{[1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 4-{{[1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 4-{{[1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;
 35 4-{{[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo}-3-hydroxybenzoic acid;

- 3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-4-hydroxybenzoic acid;
3-hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
5 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;
3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid;
2-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
10 5-chloro-3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzenesulfonic acid;
3-*tert*-butyl-4-([1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
15 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
methyl 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoate; and
4-([1-(4-*tert*-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;
20 and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.

5. A pharmaceutical composition for use in enhancing platelet production which comprises a compound of Formula (II), as described in Claim 1, and a pharmaceutically acceptable carrier.
25

6. Use of a compound of Formula (II), as described in Claim 1, in the manufacture of a medicament for use in treating of thrombocytopenia.

- 30 7. A method of activating the TPO receptor which comprises administering a compound of Formula (II), as described in Claim 1.


8. The method of Claim 1 wherein the compound is administered orally.

- 35 9. The method of Claim 1 wherein the compound is administered parenterally.

10. A method of agonizing the TPO receptor in a subject which comprises administering an effective amount of a compound of Formula (II), as described in Claim 1.

5 11. A method of agonizing the TPO receptor in a subject which comprises administering an effective amount of a compound of Formula (II), as described in Claim 1.

10 12. A compound represented by the following Formula (I)



wherein:

15 R, R¹, R², R³ and R⁹ are each independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_pOR⁴, -C(O)OR⁴, nitro, cyano, halogen, aryl, -S(O)_nR⁴, cycloalkyl, protected -OH, -CONR⁵R⁶, phosphonic acid, sulfonic acid, phosphinic acid and -SO₂NR⁵R⁶,

where

20 p is 0-6;

n is 0-2;

R⁴ is hydrogen, alkyl, cycloalkyl, C₁-C₁₂aryl, substituted alkyl, substituted cycloalkyl and substituted C₁-C₁₂aryl, and

R⁵ and R⁶ are each independently selected from hydrogen, alkyl, C₃₋

25 6cycloalkyl, aryl or R⁵ and R⁶ taken together with the nitrogen to which they are attached represent a 5 to 6 member saturated ring containing up to one other heteroatom selected from oxygen and nitrogen;

m is 0-6; and

R¹⁰ is a cyclic or polycyclic aromatic ring containing from 3 to 16 carbon atoms and optionally containing one or more heteroatoms, provided that when the number of carbon atoms is 3 the aromatic ring contains at least two heteroatoms and when the number of carbon atoms is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of: alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aryloxy, alkoxy, acyloxy, amino, nitro, cyano, halogen, hydroxy, protected -OH, and alkyl substituted with one or more substituents selected from the group consisting of: alkoxy, acyloxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, aryloxy, amino, nitro, cyano, halogen, hydroxy, and protected -OH; and pharmaceutically acceptable salts, hydrates, solvates and esters thereof;

provided that:

at least one of R, R¹, R² and R³ is: sulfonic acid, -C(O)OR⁴, tetrazole, -CONR⁵R⁶, phosphonic acid or phosphinic acid; where R⁴, R⁵ and R⁶ are as described above;

and provided that:

when R¹ is carboxylic acid; R, R² and R³ are hydrogen; and R⁹ is methyl; R¹⁰ is not unsubstituted phenyl.

13. A compound of claim 12 selected from

3-hydroxy-4-[[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo]benzoic acid;

4-[[1-(4-benzyloxyphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;

4-[[1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;

4-[[1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;

4-[[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxybenzoic acid;

3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-4-hydroxybenzoic acid;

3-hydroxy-4-([5-hydroxy-3-methyl-1-(3-methylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;

5 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]azo)benzoic acid;

3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzoic acid;

10 2-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;

5-chloro-3-([1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-2-hydroxybenzenesulfonic acid;

3-*tert*-butyl-4-([1-(3,4-dimethylphenyl)-5-hydroxy-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;


15 4-([1-(3,4-dimethylphenyl)-5-hydroxy-3-phenyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;

methyl 3-hydroxy-4-([5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]azo)benzoate; and


20 4-([1-(4-*tert*-butylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo)-3-hydroxybenzoic acid;

and pharmaceutically acceptable salts, hydrates, solvates and esters thereof.


14. A process for the preparation of a compound of Formula (I)



25 or a pharmaceutically acceptable salt, hydrate or solvate thereof,
wherein R , R^1 , R^2 , R^3 , R^9 , R^{10} and m are as described in Claim 12; which comprises:
reacting a compound of the following formula (i),



wherein R, R¹, R², R³ and m are as described in Claim 12 with a nitrite and an acid to form a diazonium compound of formula (ii),



- 5 wherein R, R¹, R², R³ and m are as described in Claim 12;
 followed by a coupling reaction with an appropriate pyrazole reactant, to form a compound
 of Formula (I),
 and thereafter optionally forming a pharmaceutically acceptable salt, hydrate or solvate
 thereof.

10

- 15 15. A process for preparing a pharmaceutical composition containing a
 pharmaceutically acceptable carrier or diluent and an effective amount of a compound
 of the Formula (II) as described in claim 1 and pharmaceutically acceptable salts,
 hydrates, solvates and esters thereof which process comprises bringing the compound
 of the Formula (II) into association with the pharmaceutically acceptable carrier or
 diluent.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/24665

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A01N 43/56; A61K 31/415; C07D 231/04

US CL :514/407; 548/366.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/407; 548/366.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
REGISTRY, HCAPLUS structure search with the following terms: duffy k/au, thrombopoiet?, thrombocytopen?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,482,546 A (EIDA) 09 January 1996, see abstract and from column 2, line 44 to column 3, line 61).	12, 13 and 15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 DECEMBER 2000

Date of mailing of the international search report

22 JAN 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DWAYNE C. JONES

Telephone No. (703) 308-1235

DELLA MAE COLLINS
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600